Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Study of Denosumab vs Alendronate in Postmenopausal Women
2005-005081-37Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in postmenopausal osteoporosis and osteopenia (2 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in total hip bone mineral density at 12 months. Started May 2006; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosisosteopenia
Beyond the preview
Go deeper on 2005-005081-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005081-37.